Answer
Yes, imlunestrant antagonises and degrades both wild-type and mutant oestrogen receptor-alpha (ERα), inhibiting oestrogen receptor-dependent gene transcription and cellular proliferation in ER-positive breast cancer cells.
Sources for this answer
- Inluriyo 200 mg film-coated tabletsEli Lilly and Company Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 1Document updated
Sources checked